Triflo Valve
Aortic and Mitral Valve Replacement
Pre-clinicalActive
Key Facts
About Novostia
Novostia is a pre-revenue, private medical device innovator based in Lausanne, Switzerland, focused on addressing significant unmet needs in cardiovascular valve replacement. Its core product, the Triflo valve, is a novel artificial heart valve engineered to combine durability, reduced blood clot risk, and quiet operation, aiming to serve patients of all ages, including children. The company is in the late preclinical stage, supported by EU Horizon 2020 funding and academic collaborations, and is preparing for first-in-human clinical trials.
View full company profile